A new ICER and West Health report finds median drug launch prices climbed to $257,000, the FDA approves GSK’s Hibsago as the first functional-cure therapy for chronic hepatitis B, and CSL names Deborah Waterhouse as CEO and managing director.
News|Articles|October 17, 2024
Patient Engagement Throughout the Entire Product Lifecycle (October 2024)
Author(s)Reverba Global
In the pharmaceutical industry, patient engagement should be centered in health education, communication, and strategy during drug discovery and throughout the product lifecycle. Cheryl Lubbert, CEO of Reverba, discusses the importance of a patient-first mindset in the industry.
Related to this article
Median Drug Launch Prices Hit $257,000 as Access Barriers Persist, ICER and West Health Report Finds
Median net launch prices for new drugs climbed between 2022 and 2025 to $257,000, according to a new ICER and West Health report that also found persistent coverage and access barriers for patients.
The FDA approved GSK's bepirovirsen for adults with chronic hepatitis B on nucleoside therapy, based on phase 3 trials showing 19% functional cure.
Deborah Waterhouse is leaving ViiV Healthcare to become CEO and managing director of CSL.
Incubate’s John Stanford on why MFN’s first casualty is the moonshot — and why cancer, Alzheimer’s, and rare disease bear the cost.
METiS TechBio and Eli Lilly collaborate on next-generation LNP delivery technology, Incubate’s John Stanford on how MFN deals may shape future pharma decisions, and the FDA grants accelerated approval to GSK’s Jemperli for MSI-H/dMMR locally advanced rectal cancer.
METiS TechBio enters a collaboration with Eli Lilly to develop next-generation, tissue-specific lipid nanoparticle delivery technologies using METiS’s AI-driven lipid discovery platform.
Incubate’s John Stanford on why MFN reduces pharma’s appetite for biotech acquisitions — and why that cedes ground to China.
Trending on PharmExec
1
CSL Names Deborah Waterhouse as CEO and Manager Director
2
FDA Approves Hibsago (Bepirovirsen) for Chronic Hepatitis B
3
The Therapeutic Areas or Deals That Might Be Negatively Impacted by MFN Deals
4
Median Drug Launch Prices Hit $257,000 as Access Barriers Persist, ICER and West Health Report Finds
5